Home Stock

Stock Research: Royalty Pharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Royalty Pharma

NasdaqGS:RPRX GB00BMVP7Y09
81
  • Value
    92
  • Growth
    57
  • Safety
    Safety
    38
  • Combined
    74
  • Sentiment
    70
  • 360° View
    360° View
    81
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Royalty Pharma plc is a buyer of biopharmaceutical royalties and funds innovation in the biopharmaceutical industry. The company operates across the biopharmaceutical industry, collaborating with various innovators from academic institutions to global pharmaceutical companies, and has a portfolio including royalties on over 35 commercial products like Vertex’s Trikafta and GSK’s Trelegy. In the last fiscal year, the company had a market cap of $20527 million, profits of NULL, revenue of $2264 million, and 99 employees.

more
Strongest Rank Market Pulse
Weakest Rank Pro Holdings
Country USA
Industry Pharmaceuticals
Size Small
Website royaltypharma.com
Index
Dividends USA
SDG 10
SDG 17
SDG 3
SDG 9
NASDAQ
Royalty Pharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
92 96 96 83
Growth
57 59 15 23
Safety
Safety
38 45 52 58
Sentiment
70 94 63 43
360° View
360° View
81 96 72 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
73 75 77 40
Opinions Change
63 89 29 72
Pro Holdings
n/a 96 55 36
Market Pulse
17 23 45 46
Sentiment
70 94 63 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
92 96 96 83
Growth
57 59 15 23
Safety Safety
38 45 52 58
Combined
74 88 59 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
89 93 95 75
Price vs. Earnings (P/E)
18 11 14 12
Price vs. Book (P/B)
59 65 60 50
Dividend Yield
88 94 94 92
Value
92 96 96 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
26 45 11 19
Profit Growth
32 37 51 57
Capital Growth
71 79 49 43
Stock Returns
80 57 33 51
Growth
57 59 15 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
46 40 44 46
Refinancing
18 14 35 27
Liquidity
69 75 75 82
Safety Safety
38 45 52 58

Similar Stocks

Discover high‑ranked alternatives to Royalty Pharma and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews